Results 151 to 160 of about 196,164 (338)

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2018
J. Seymour, T. Kipps, B. Eichhorst, P. Hillmen, J. D’Rozario, S. Assouline, C. Owen, J. Gerecitano, T. Robak, J. de la Serna, U. Jaeger, G. Cartron, M. Montillo, R. Humerickhouse, E. Punnoose, Yan Li, M. Boyer, K. Humphrey, M. Mobasher, A. Kater   +19 more
semanticscholar   +1 more source

Lifelong evolution of autoreactive plasma cell numbers, affinity and anatomical location in arthritic K/BxN mice

Arthritis &Rheumatology, Accepted Article.
Objective The spontaneous K/BxN mouse model of rheumatoid arthritis has been used extensively to study chronic inflammation, contribution of immune cells, and the primordial role of autoreactive antibodies in disease initiation and severity. Only the ubiquitous enzyme glucose‐6‐phosphate isomerase (GPI) is the target of IgG autoantibodies secreted by ...
Thibault Vanhoucke, Carlos Castrillon, Odile Richard‐Le Goff, Angga Perima, Matteo Broketa, Andrew D. Griffiths, Patrick England, François Huetz, Pierre Bruhns   +8 more
wiley   +1 more source

Rituximab treatment has long-term effects in MuSK myasthenia gravis [PDF]

, 2012

openalex   +1 more source

Molecular stratification of antiphospholipid syndrome through integrative analysis of the whole‐blood RNA transcriptome

Arthritis &Rheumatology, Accepted Article.
Objective Antiphospholipid syndrome (APS) is a thrombo‐inflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)‐positive patients using whole‐blood transcriptomics.
Amala Ambati, Feiyang Ma, Katarina Kmetova, Sherwin Navaz, Claire K. Hoy, Cyrus Sarosh, Ajay Tambralli, Erika Navarro‐Mendoza, Johann E. Gudjonsson, J. Michelle Kahlenberg, Jacqueline A. Madison, Alí Duarte‐García, Jason S. Knight, Yu Zuo   +13 more
wiley   +1 more source

Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

, 2021
Duanfeng Jiang, Qiuyu Mo, Xiaoying Sun, Xiaotao Wang, Min Dong, Guozhen Zhang, Fangping Chen, Qiangqiang Zhao   +7 more
openalex   +1 more source

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

New England Journal of Medicine, 2004
J. Edwards, L. Szczepanski, J. Szechiński, A. Filipowicz-Sosnowska, P. Emery, D. Close, R. Stevens, T. Shaw   +7 more
semanticscholar   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

Arthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators   +10 more
wiley   +1 more source

Long‐Term Outcomes of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Systemic Sclerosis Patients with Impaired Cardiac Function

Arthritis &Rheumatology, Accepted Article.
Objective High intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced SSc. The role of reduced intensity conditioning (RIC) prior to AHSCT in this population remains unclear. We conducted this study to determine the long‐term outcomes of RIC AHSCT in SSc patients with cardiac ...
Yonatan Lean, Carrie Richardson, Anthony Esposito, Katy Bedjeti, George E. Georges   +4 more
wiley   +1 more source

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

New England Journal of Medicine, 2010
John H. Stone, Peter A. Merkel, R. Spiera, P. Seo, C. Langford, G. Hoffman, C. Kallenberg, E. St. Clair, A. Turkiewicz, N. Tchao, L. Webber, L. Ding, Lourdes P. Sejismundo, Kathleen Mieras, D. Weitzenkamp, D. Ikle, V. Seyfert-Margolis, Mark Mueller, P. Brunetta, Nancy B. Allen, F. Fervenza, D. Geetha, K. Keogh, E. Kissin, P. Monach, T. Peikert, C. Stegeman, S. Ytterberg, U. Specks   +28 more
semanticscholar   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source